Posted by Michael Wonder on 03 Jun 2020
Clarity Pharmaceuticals announces that the US FDA grants rare paediatric disease designation to Copper Cu 67 sartate for the treatment of neuroblastoma
3 June 2020 - Clarity Pharmaceuticals is pleased to announce that the U.S. FDA has granted rare paediatric disease designation to Copper Cu 67 sartate, a therapy for the clinical management of neuroblastoma.
Upon FDA marketing approval of Copper Cu 67 sartate for neuroblastoma with rare paediatric disease designation, Clarity may be eligible to receive a priority review voucher, which can be used to obtain FDA review of a new drug application for another product in an expedited period of six months.
The voucher may also be sold or transferred and to date they have been sold for between US$67.5 million to US$350 million.
